Trial Profile
A post-authorization, multicenter, non- interventional, safety study using HSA-free scIFNβ-1a in patients with multiple sclerosis.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms STEP
- 12 Nov 2016 New trial record
- 17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis